Uncovering subclinical cardiotoxicity across chemotherapy phases in pediatric oncology.

ABSTRACT:

Background and objectives

Advances in cancer therapies have significantly improved survival rates in children. However, treatment-related toxicities remain common. This study aims to evaluate the incidence and characteristics of cardiotoxicity in a pediatric cancer cohort.

Methods

This prospective study included pediatric patients who received chemotherapy between September 2020 and March 2023. Patients were categorized into five groups according to treatment phase: baseline, early treatment, late treatment, end-of-treatment, and relapse. Cardiovascular evaluation included anthropometric assessment, laboratory biomarkers, electrocardiogram (ECG) and functional echocardiography. Patients were stratified for cardiotoxicity according to pediatric and adult clinical practice gui

SUBMITTER: Aurensanz-Clemente E 

PROVIDER: S-EPMC12507561 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature